Abstracts Archive - Page 2033 of 2425 - ACR Meeting Abstracts

Abstract Number: 291 • 2014 ACR/ARHP Annual Meeting
Development of a Serious Game Designed for Children with Juvenile Idiopathic Arthritis
Jean-David Cohen¹, Damien Bentayou², Marcantoine Bernard-Brunel³ and Sonia Tropé⁴, ¹IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, ²Art Director, CG Artist, PESSAC, France, ³Programmer, CG Artist, PESSAC, France, ⁴149 avenue du Maine, ANDAR, Paris, France
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is the most common chronic paediatric rheumatic disease and cause of physical and psychological disability, with family and school consequences.…
Abstract Number: 290 • 2014 ACR/ARHP Annual Meeting
Patterns of Active Joint Involvement in JIA
Simon W.M. Eng¹, Mira Van Veenendaal², Alan M. Rosenberg³, Kiem Oen⁴, Quaid Morris¹ and Rae S.M. Yeung², ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Pediatrics RR149 Rehab Ctr, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: JIA encompasses a set of heterogeneous diseases with chronic joint inflammation. Although the ILAR criteria consider joint counts, they do not reflect specific joint…
Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Gerd Horneff¹, Carol A. Wallace², Pierre Quartier³, Daniel J. Kingsbury⁴, Kirsten Minden⁵, Mareike Bereswill⁶, Vishvas Garg⁷, Hartmut Kupper⁶ and Jasmina Kalabic⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴Randall Children's Hospital at Legacy Emanuel, Portland, OR, ⁵Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…
Abstract Number: 258 • 2014 ACR/ARHP Annual Meeting
Pain Characteristics Among Patients with Rheumatoid Arthritis in the Context of Patient-Physician Discordance in Disease Activity Assessments
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Healthcare must be patient-centered to achieve optimal outcomes and quality of life. From this perspective, it is significant that patients with rheumatoid arthritis (RA)…
Abstract Number: 274 • 2014 ACR/ARHP Annual Meeting
Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study
Rebecca Davies¹, Roberto Carrasco², Helen Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Yiannis Ioannou⁷, Lucy R. Wedderburn⁸, Wendy Thomson⁹, Kimme L. Hyrich¹⁰ and on Behalf Of Childhood Arthritis Prospective Study (CAPS)¹¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Newcastle University, Newcastle, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ¹⁰Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹¹university of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogenous disease, classified according to the International League of Associations for Rheumatology (ILAR). Initial treatment is based largely…
Abstract Number: 275 • 2014 ACR/ARHP Annual Meeting
Environmental Risk Factors and Development of Juvenile Idiopathic Arthritis
Susan Shenoi¹, Kathryn B Whitlock² and Carol A Wallace³, ¹Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, ²Core for Biomedical Statistics, Seattle Children's Hosptial, Seattle, WA, ³Pediatric Rheumatology, Seattle Children's Hospital/Univ of Washington, Seattle, WA
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is a heterogenous group of disorders that is characterized by chronic arthritis in children without known etiology. Environmental factors that…
Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Carol A. Wallace³, Mary Toth⁴, Ivan Foeldvari⁵, John Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Pavla Vavrincova⁹, Daniel J. Kingsbury¹⁰, Katherine Marzan¹¹, Pierre Quartier¹², Kirsten Minden¹³, Elizabeth Chalom¹, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason Dare¹⁶, Mareike Bereswill¹⁷, Hartmut Kupper¹⁷, Jasmina Kalabic¹⁷, Daniel Lovell¹⁸ and Alberto Martini¹⁹, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NC, ⁹Fakultni nemocnice v Motole, Praha, Czech Republic, ¹⁰Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹³Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁹PRINTO-IRCCS, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…
Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Rebecca Davies¹, Lianne Kearsley-Fleet¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson⁶, Kimme L. Hyrich⁷, on Behalf Of The BSPAR Etanercept Cohort Study¹ and The Biologics for Children with Rheumatic Diseases (BCRD) study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…
Abstract Number: 270 • 2014 ACR/ARHP Annual Meeting
Disease Burden Is Comparable in Children with Enthesitis-Related Arthritis and Polyarticular Juvenile Idiopathic Arthritis
Pierre Quartier¹, Jasmina Kalabic², Zbigniew Zuber³, Kirsten Minden⁴ and Jaclyn K. Anderson⁵, ¹Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ³St. Louis Children’s Hospital, Krakow, Poland, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: To compare baseline disease characteristics of pediatric patients (pts) with enthesitis-related arthritis (ERA) and polyarticular juvenile idiopathic arthritis (pJIA) from clinical trials with adalimumab…
Abstract Number: 269 • 2014 ACR/ARHP Annual Meeting
Discontinuation of Concomitant Medication for Enthesitis-Related Arthritis during 52 Weeks of Treatment with Adalimumab
Shirley ML Tse¹, Rubén Burgos-Vargas², Gerd Horneff³, Aileen L. Pangan⁴, Jasmina Kalabic⁵, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁴, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Children with enthesitis-related arthritis (ERA) require medical therapy to control inflammation and restore normal function; however, the use of multiple medications and for longer…
Abstract Number: 268 • 2014 ACR/ARHP Annual Meeting
The Effect of Treatment with Resiniferatoxin and Capsaicin on Dynamic Weight Bearing Measures and Evoked Pain Responses in a Chronic Inflammatory Arthritis Murine Model
Joseph Bert¹, Christopher W. Dorman², Sandra Frizelle², Sonia C. Funkenbusch², Hollis E. Krug³ and Maren L. Mahowald⁴, ¹Internal Medicine, University of Minnesota Internal Medicine Residency, Minneapolis, MN, ²Research, Minneapolis VA Health Care System, Minneapolis, MN, ³Medicine, VA Health Care System, Minneapolis, MN, ⁴Medicine, University of Minnesota Medical School and Minneapolis VA Health Care System, Minneapolis, MN
Background/Purpose: Capsaicin (CAP) and Resiniferatoxin (RTX) are vanilloid receptor agonists that when given by intra-articular injections, can normalize Evoked Pain Scores (EPS) and Automated Dynamic…
Abstract Number: 266 • 2014 ACR/ARHP Annual Meeting
An Examination of the Interaction of Opioid Use, Pain, and Depression
Jenna Goesling¹, Matthew Henry², Stephanie Moser³, Paul Hilliard⁴, Afton L. Hassett¹ and Chad Brummett⁴, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI
Background/Purpose In the past two decades there has been an increase in the use of opioids to treat chronic pain. Despite this trend, there is…
Abstract Number: 265 • 2014 ACR/ARHP Annual Meeting
Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study
Peter A. Ste-Marie¹, Yoram Shir¹, Emmanouil Rampakakis², John S. Sampalis^2,3, Martin Cohen⁴, Michael Starr⁵, Mark A Ware¹ and Mary-Ann Fitzcharles⁶, ¹Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴Rheumatology, Mcgill University Health Centre, Montreal, QC, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: With a worldwide groundswell of interest in cannabinoids as a possible treatment option for persons with rheumatic diseases, and with few pharmacologic cannabinoid options…
Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Tara Landry¹, Mary-Ann Fitzcharles², Peter A. Ste-Marie³ and Yoram Shir³, ¹Montreal General Hospital Medical Library, Mcgill University Health Centre, Montreal, QC, Canada, ²Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].